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ABSTRACT: Arsenic is the most ubiquitous environmental toxin and carcinogen. Long-
term exposure to arsenic is associated with human diseases including cancer, cardiovascular
disease, and diabetes. Human As(III) S-adenosylmethionine (SAM) methyltransferases
(hAS3MT) methylates As(III) to trivalent mono- and dimethyl species that are more toxic
and potentially more carcinogenic than inorganic arsenic. Modulators of hAS3MT activity
may be useful for the prevention or treatment of arsenic-related diseases. Using a newly
developed high-throughput assay for hAS3MT activity, we identiﬁed 10 novel
noncompetitive small molecule inhibitors. In silico docking analysis with the crystal
structure of an AS3MT orthologue suggests that the inhibitors bind in a cleft between
domains that is distant from either the As(III) or SAM binding sites. This suggests the
presence of a possible allosteric and regulatory site in the enzyme. These inhibitors may be
useful tools for future research in arsenic metabolism and are the starting-point for the
development of drugs against hAS3MT.
■ INTRODUCTION
Arsenic is the most pervasive environmental toxin; con-
sequently, the U.S. Environmental Protection Agency (EPA)
and Agency for Toxic Substances and Disease Registry
(ATSDR) rank arsenic ﬁrst on the U.S. Priority List of
Hazardous Substances (http://www.atsdr.cdc.gov/SPL/index.
html). The EPA asserts that it pervades our drinking water,1
and the U.S. Food and Drug Administration is concerned about
arsenic endangering the safety of our food supply (http://www.
fda.gov/Food/FoodborneIllnessContaminants/Metals/
ucm319870.htm). For example, arsenic in rice has been
associated with increased risk of cancer in Chinese
populations.2 The eﬀects of arsenic exposure is not limited to
cancer; there is a strong correlation between dietary arsenic and
cardiovascular disease,3 diabetes,4,5 and other human disor-
ders.6
In humans, arsenic is primarily metabolized by the enzyme
As(III) SAM methyltransferase (hAS3MT), a member of the
large superfamily of SAM methyltransferases (SAM MTs).
Methylation was originally considered as a detoxiﬁcation
process but is now thought to transform arsenic into more
toxic species.7 AS3MT biotransforms of inorganic arsenic
(As(III)) into trivalent methylated species methylarsenite
(MAs(III)) and dimethylarsenite (DMAs(III)) using SAM as
the methyl donor.8,9 The trivalent methylarsenicals are excreted
in urine, where they oxidize to pentavalent methylarsenate
(MAs(V)) and dimethylarsenate (DMAs(V)).10−12 hAS3MT is
an example of a “Phase II” enzyme that is simultaneously
protective but also activates arsenic into more toxic and
potentially carcinogenic organoarsenicals.13
How would more or less hAS3MT activity aﬀect
susceptibility to arsenic-related diseases? On the one hand, it
seems reasonable to consider that lower rates of methylation
would be protective. If so, drugs that inhibit AS3MT would be
useful for prevention or treatment of arsenic-related diseases.
However, it is not known whether humans require AS3MT, or
what the physiological consequences of its absence might be.
AS3MT knockout mice have reduced arsenic methylation14 and
are sensitive to high levels of arsenic.15 However, mice do not
develop arsenic-related bladder cancer, so the mouse may not
be the best model for arsenic carcinogenesis in humans.16
On the other hand, more rapid production of methylated
species can lead to faster urinary excretion, and higher clearance
rates might be protective. In that case, drugs that activate
AS3MT might be valuable. Individuals who excrete more
DMAs in urine have lower rates of bladder cancer and other
arsenic-related diseases.17 Conversely, higher DMAs is also
associated with increased incidence of diabetes5 and is
considered to be a carcinogen in rats at high concentra-
tions.18,19 Thus, it is not clear whether drug development
should be directed toward inhibitors or activators of AS3MT.
To date, only nonspeciﬁc inhibitors of AS3MT have been
identiﬁed.20 The objective of this study was to identify small
molecules that bind to hAS3MT and modulate its activity. In
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this report, we adapted a commercial methyltransferase method
for use as a rapid and sensitive microplate assay to identify
inhibitors of AS3MT activity. The assay utilizes time-resolved
Förster (ﬂuorescence) resonance energy transfer (TR-FRET)
to directly measure conversion of SAM to S-adenosylhomo-
cysteine (SAH). This assay uses terbium FRET with an anti-
SAH antibody labeled with a Tb(III) cryptate and a SAH-dye
acceptor. We screened the Torrey Pines Institute for Molecular
Studies (TPIMS) scaﬀold ranking compound libraries that
consist of more than 30 million small molecules. The TPIMS
compounds were designed around 70 molecular scaﬀolds
systematically arranged in positional scanning and scaﬀold
ranking formats.21,22 This approach has been successfully used
to isolate compounds selective for their targets, for example,
selective α4β2 nAChR antagonists.23 We identiﬁed 10
compounds that inhibit hAS3MT with IC50 values of the
order of 30−50 μM. None of the compounds inhibit the
binding of either As(III) or MAs(III), and they do not inhibit
catachol o-methyltransferase (COMT), a nonarsenic SAM
MT.24 Thus, they appear to be noncompetitive inhibitors
selective for AS3MT. In silico docking analysis of the inhibitors
to the crystal structure of an AS3MT orthologue25 indicates
that the TPIMS molecules bind in a cleft in the enzyme located
distant from the As(III) and SAM binding sites. The inhibitor
binding location may be an allosteric regulatory site, which
implies the existence of physiological regulators of arsenic
methylation. These are the ﬁrst identiﬁed selective small
molecule inhibitors of hAS3MT. They provide a scaﬀold for
future rational design of clinically useful drugs that modulate
hAS3MT activity and may also be useful probes for further
research into AS3MT function.
■ MATERIALS AND METHODS
Reagents. SAM was purchased from Cayman Chemical Co. (Ann
Arbor, MI). Boric acid was purchased from Fisher Scientiﬁc
(Pittsburgh, PA). All other reagents were purchased from Sigma
Chemical Co. (St. Louis, MO), as was porcine catechol O-
methyltransferase. The EPIgeneous Methyltransferase Assay kit was
purchased from Cisbio Assays (Bedford, MA). Tris(2-carboxyethyl)-
phosphine (TCEP) was prepared as a 0.5 M stock solution adjusted to
pH 7.0. MAs(V) was reduced to MAs(III) as described
previously.20,26,27
Puriﬁcation of AS3MT Enzymes. hAS3MT, Chlamydomonas
reinhardtii CrAS3MT, and its single-tryptophan derivative Y72W were
puriﬁed by Ni-NTA chromatography from cells of Escherichia coli, as
described previously.9,20
Synthesis of TPIMS Compounds. Individual TPIMS compounds
TPI-1 through TPI-11 were synthesized using the general approaches
described previously (Figure S1).28,29 The parallel solid phase
synthesis was performed using the tea-bag method.30 The initial
acylated peptides were made using standard Boc chemistry conditions
with diisopropylcarbodiimide and 1-hydroxybenzotriazole hydrate as
the activating reagents. Boc-Phenylalanine was used for the R1
position of TPI-3 through TPI-11, Boc-tyrosine(2-Br-Z) for TPI-1,
and Boc-D-naphthylalanine for TPI-2. Boc-phenylalanine was used for
the R2 and R3 positions of all 11 compounds. The following
carboxylic acids were used for the R4 position: phenylacetic acid (TPI-
1 and TPI-2), 3-bromophenylacetic acid (TPI-3), 4-isobutyl-alpha-
methylphenylacetic acid (TPI-4), 3,4-dichlorophenylacetic acid (TPI-
5), cyclohexanebutyric acid (TPI-6), cyclohexanepropionic acid (TPI-
7), 4-tert-butyl-cyclohexancecarboxylic acid (TPI-8), 4-biphenylacetic
acid (TPI-9), 1-adamantancecarboxylic acid (TPI-10), and isobutyric
acid (TPI-11). The amide bonds were reduced using a 1.0 M borane
tethahydrofuran (THF) complex solution (40-fold excess per amide)
heated at 65 °C for 72 h followed by overnight treatment with
piperidine at 65 °C. The guanidine cyclization was accomplished using
a 5-fold excess of cyanogen bromide (CNBr) in a 0.1 M anhydrous
solution of dichloromethane. After cyclization, the compounds were
removed from the solid support with a solution of hydrogen ﬂuoride
(HF), 0 °C for 1 h.
TR-FRET Assay of Methyltransferase Activity. AS3MT activity
was determed with an EPIgeneous Methyltransferase Assay kit by
assaying the conversion of SAM to SAH according to the
manufacturer’s directions. The assay was carried out using a low
volume 384-well microtiter plate in a buﬀer consisting of 50 mM
MOPS, pH 7.5, containing 0.15 M KCl, 10 μM SAM, 10 μM As(III),
20 μM TCEP, and TPIMS inhibitors, as indicated. Puriﬁed CrAS3MT
or hAS3MT at 1 μM, ﬁnal concentration, was added to initiate the
reaction. The reactions were carried out for 5 min at either room
temperature or 37 °C, as indicated. The reaction was terminated and
developed by the addition of SAH-d2 and anti-SAH-Lumi4-Tb
detection reagents. The plates were incubated for 1 h, and ﬂuorescence
was measured at both 665 and 620 nm with excitation at 337 nm in a
Synergy H4 Hybrid Multi-Mode microplate reader. The homogeneous
time-resolved ﬂuorescence (HTRF) was calculated from the ratio of
emission at 665 and 620 nm. The concentration of SAH was calculated
with a calibration curve constructed with known concentrations of
SAH.
ICP-MS Assay of Arsenic Methylation. Arsenic methylation was
assayed as described previously31 in a buﬀer consisting of 50 mM
NaH2PO4, pH 8.0, containing 0.3 M NaCl, 0.5 mM SAM, 10 μM
As(III), and 1 mM TCEP and TPIMS inhibitors, as indicated. Puriﬁed
hAS3MT was added at 2 μM, ﬁnal concentration, to initiate the
reaction. The reactions were carried out at 37 °C for 4 h, at which time
they were terminated by the addition of H2O2 at 6%, ﬁnal
concentration. The assay solution was immediately passed through a
3 kDa cutoﬀ Amicon ultraﬁlter (Millipore, Billerica, MA). Arsenic
speciation was determined by high pressure liquid chromatography
(HPLC) (PerkinElmer Series 2000) with a C18 300A reverse-phase
column (Chromservis s.r.o., Brno, Czech Republic), with arsenic
measured by inductively coupled plasma mass spectrometry (ICP-MS)
using an ELAN 9000 (PerkinElmer, Waltham, MA).
Assay for Catechol O-Methyl Transferase Activity. Catechol
O-methyltransferase was assayed as described.24 The assay was carried
out in 30 μL of a buﬀer consisting of 40 mM TES, pH 7.6, containing
0.1 mM dihydroxyacetone phosphate, 1.2 mM MgCl2, 4 mM DTT,
and 0.6 units of COMT. TPI compounds or sinefungin were added as
indicated. The reaction was initiated by the addition of 1 mM SAM,
ﬁnal concentration. After 2 h at 37 °C, the reaction was terminated by
the addition of 0.2 M sodium borate, pH 10.0, ﬁnal concentration.
Total methylated products were estimated from the absorption at 344
nm using a Synergy H4 Hybrid Multi-Mode microplate reader.
Assays of Substrate-Dependent Quenching of Tryptophan
Fluorescence. Measurement of protein ﬂuorescence of puriﬁed
CrAS3MT Y72W were assayed in 384 well microtiter plates with a
total volume of 15 μL of a buﬀer consisting of 50 mM MOPS-KOH,
pH 7.5, containing 0.15 M KCl, and 5 μM Y72W CrAS3MT, ﬁnal
concentration. Substrates were added to the assay buﬀer to initiate the
reaction. Protein ﬂuorescence was determined with a Synergy H4
Hybrid Multi-Mode microplate reader, with excitation and emission
wavelengths of 295 and 345 nm, respectively.
In Silico Docking Analysis. The TPIMS molecules were
converted to 3D structures using the Open Babel program (http://
openbabel.org/) and saved in Protein Data Bank (PDB) format.
Further energy minimization was performed by employing the Dundee
PRODRG server (http://davapc1.bioch.dundee.ac.uk/cgi-bin/
prodrg). Graphical user interface program AutoDockTools 1.5.632
was used to merge nonpolar hydrogens, add Gasteiger charges, and set
rotatable bonds. Finally, all ligands were saved in PDBQT ﬁle format
for use by AutoDock Vina (ADVina).33 The CmArsM (4FS8) and
COMT (3BWM) structures were prepared for docking analysis by
removing the water molecules and cofactors/ligands from the PDB
ﬁles, assigning polar hydrogens, adding Gasteiger charges, and ﬁnally
selecting the proteins as rigid models using AutoDockTools 1.5.6. The
TPIMS inhibitors were docked with the two proteins using the open
source docking program ADVina. A docking grid search space volume
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was employed with a size of 30 Å × 30 Å × 30 Å for a grid spacing of 1
Å, and the grid center was ﬁxed at the dimensions (X, Y, Z) 6.683,
−2.966, Z = 23.928 (for 4FS8), and (X, Y, Z) −8.839, −5.628, −9.694
(for 3BWM), respectively. The exhaustiveness parameter in ADVina
was set at 9. All automated docking evaluations by Vina employed
iteration with local search global optimization. The docked score
results are given as most favorable free energy of binding (ΔG) and are
clustered together within the 1 Å positional root-mean squared
deviation (RMSD). Predicted molar dissociation constants (Kd) were
calculated from the ΔG values using the relationship Kd = exp(ΔG/
RT), where R is 1.9872, and T is 298.15 K. Molecular models were
generated using PyMol.34
■ RESULTS
Screening of Compound Scaﬀold Ranking Libraries.
Two AS3MT orthologues were used in this study. Human
hAS3MT was puriﬁed by the expression of a synthetic gene that
produces a highly active form of the enzyme.9 The second
CrAS3MT (also called CrArsM) is an AS3MT orthologue from
the eukaryotic alga Chlamydomonas reinhardtii.35 Homology
models of hAS3MT and CrAS3MT based on the crystal
structure of the orthologue from the alga Cyanidioschyzon
merolae (termed CmArsM or CmAS3MT)25 shows that the
two structures are overall superimposible.9 Initial screening was
performed with CrAS3MT because it has robust activity at
room temperature, while hAS3MT has a temperature optimum
of 37 °C.
A newly developed TR-FRET assay for AS3MT activity that
is both rapid and highly sensitive was used for high throughput
screening of potential AS3MT inhibitors.20 Utilizing the
TPIMS Scaﬀold Ranking Library, which contained over 30
million synthetic compounds systematically arranged into 70
samples,22,23 the core bisguanidine pyrrolide scaﬀold (Figure
S2) was identiﬁed as the scaﬀold most likely to provide
individual inhibitory compounds. From these initial results, a
set of individual compounds all containing the bisguanidine
pyrrolide core with diﬀering R groups was screened. Ten
compounds, designated TPI-1 to TPI-10, inhibited CrAS3MT
methylation activity by at least 75% (Figures 1 and 2). The
eﬀect of the putative inhibitors on hAS3MT activity was
examined. Each of the 10 TPIMS compounds inhibited
hAS3MT with IC50 values in the range of 30 to 50 μM. As
examples, compounds TPI-2, TPI-4, TPI-5, and TPI-6 showed
IC50 values of 38, 51, 31, and 38 μM, respectively (Figure 2).
Eight of the active inhibitors diﬀer only in R4. One compound,
TPI-11, that did not inhibit also has the same R1, R2, and R3
groups as the inhibitors TPI-3 through TPI-10. The only
diﬀerence between these 8 inhibitors and TPI-11 occurs in the
substitution at the R4 position. TPI-11 contains an isobutyl
group at the R4 position which is signiﬁcantly less bulky than
any of the other functional groups contained in the inhibitors
suggesting that the size of the functional group at this position
may contribute to the compound’s ability to inhibit.
AS3MT TPIMS Inhibitors Do Not Inhibit COMT, a
Nonarsenic SAM MT. The eﬀect of TPI-4 on the activity of
porcine liver COMT was examined. No inhibition of COMT
activity activity was observed (Figure S3). In contrast,
singfungin, a SAM analogue, signiﬁcantly inhibited COMT
activity. This indicates ﬁrst that TPI-4 does not inhibit SAM
binding and second and more importantly that the small
molecule inhibitor is selective for AS3MT.
Eﬀects of TPIMS Inhibitors on the First and Second
Methylation Steps. AS3MT methylates arsenic at least twice,
As(III) → MAs(III) and MAs(III) → DMAs(III), which is
rapidly oxidized to DMAs(V) in air.12,36 We determined the
eﬀect of the small molecule inhibitors individually on the ﬁrst
and second methylation steps. The TR-FRET assay measures
primarily the ﬁrst methylation step, and each of the 10
compounds inhibits the ﬁrst methylation step. To examine the
eﬀect on the second methylation step, we used the conven-
tional assay for arsenic biotransformations, separation of the
species by reverse phase HPLC coupled to arsenic detection by
ICP-MS after reaction times of tens of minutes to hours.37
When the substrate is As(III), DMAs(V) is the primary ﬁnal
compound, a combination of both the ﬁrst and second
methylation steps. However, when MAs(III) is used as
substrate, only the second methylation step occurs. Thus, the
eﬀect of the small molecule compounds could be examined
individually on each step. Each TPIMS compound inhibited
As(III) methylation (Figure 3A). Five, TPI-2, TPI-4, TPI-6,
TPI-8, and TPI-9, inhibited MAs(III) methylation (Figure 3B).
In contrast, the other ﬁve, TPI-1, TPI-3, TPI5, TPI-7, and TPI-
10, did not inhibit MAs(III) methylation at the highest available
concentration (Figure 3C). These results suggest that all 10
TPIMS compounds inhibited the ﬁrst methylation step (As(III)
→MAs(III)), while only 5 are eﬀective inhibitors of the second
step (MAs(III) → DMAs(III)).
Eﬀect of Small Molecule Inhibitors on As(III) Binding
to hAS3MT. To examine whether inhibition of catalytic
activity resulted from the inhibition of substrate binding, a
ﬂuorescent assay for As(III) binding was employed. As(III) is
bound to two conserved cysteine residues in members of the
AS3MT family.9,38 Adjacent to the As(III) binding site is a
tyrosine residue. When this residue is mutated to a tryptophan
residue, the enzyme exhibits quenching of intrinsic protein
ﬂuorescence when either As(III) or MAs(III) is bound. The
corresponding CrAS3MT residue, Tyr72, was mutated to
tryptophan, providing a spectroscopic probe for the binding of
substrates.20 Two TPIMS compounds, TPI-2 and TPI-9, were
ﬂuorescent and could not be used in this assay. The other eight
had little eﬀect on the ﬂuorescence of free tryptophan, and their
eﬀect on the protein ﬂuorescence of the Y72W construct was
examined. The protein was incubated with the small molecule
Figure 1. Inhibition of AS3MT activity by TPIMS inhibitors.
Methyltranserase activity was assayed with CrAS3MT using the TR-
FRET method, as described under Materials and Methods. As(III) was
added at 10 μM, SAM was added at 20 μM, and small molecule
compounds were added at 50 μM, ﬁnal concentrations. The reaction
was initiated by the addition of enzyme at 1 μM, ﬁnal concentration.
The reaction was terminated after 5 min at room temperature, and
SAH production analyzed. The data are the mean ± SE (n = 3). The
dotted line indicates 75% inhibition.
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inhibitors for 5 min and then titrated with either As(III)
(Figure 4A) or MAs(III) (Figure 4B). In no case was there
signiﬁcant reduction of ﬂuorescence quenching with either
As(III) or MAs(III), indicating that the small molecule
compounds do not competitively inhibit substrate binding.
In Silico Docking Analysis Inhibitor Binding to
AS3MT. A virtual screening approach using Autodock Vina
was applied to calculate the lowest free energy binding site for
the 10 small molecule inhibitors (Table 1).33 The only available
crystal structure of an AS3MT, that from C. merolae, was used
for the docking studies.25 From the structure, three domains
have been identiﬁed, an N-terminal domain with the SAM
binding site, a middle domain with the As(III) binding site, and
a C-terminal domain of unknown function. Both the As(III)
binding site and C-terminal domain are unique to AS3MTs and
are not found in other SAM MTs. All 10 TPIMS compounds
bound in a cleft between the ﬁrst and third domains located on
the opposite side of the protein from the As(III) and SAM
binding sites, as illustrated with TPI-4 (Figure 5). The
placement of the R groups in the models varied, but since in
silico analysis provides predictions and not experimental results,
the more important ﬁnding is that they all bound in the same
cleft on the surface of the enzyme. From the calculated free
energy of binding, it is clear that each of the inhibitors are
predicted to bind to AS3MT with high aﬃnity (Table 1). In
contrast, the predicted aﬃnity of binding of TPIMS
compounds to COMT was several orders of magnitude lower
than to AS3MT, and the predicted binding site overlaps with
the catechol binding site (Figure 5).
■ DISCUSSION
AS3MT catalyzes the formation of highly toxic trivalent
methylated products9,39,40 that may also be more carcinogenic
than inorganic arsenite.41,42 In microbes, AS3MT-catalyzed
methylation of As(III) is clearly a detoxiﬁcation process.43 In
humans and other animals, arsenic methylation is paradoxically
a detoxiﬁcation process, but, in the long term, AS3MT activates
arsenic into a more toxic and carcinogen species.41,44 Could
modulation of human hAS3MT prevent or alleviate arsenic-
related diseases? There are two possibilities: (1) inhibitors of
hAS3MT could prevent the formation of MAs(III) and
DMAs(III), or (2) activators of hAS3MT could increase
clearance of arsenic in urine. Inhibition of hAS3MT might
increase acute toxicity, as observed in knockout mice,15 but
humans are rarely exposed to levels of arsenic that produce
acute toxicity. Activation of hAS3MT might reduce the overall
body burden, but it would not prevent the generation of
intracellular MAs(III) and DMAs(III) and would not prevent
intracellular events such as generation of reactive oxidative
species or DNA damage. Which, if either, alternative would
provide beneﬁcial outcomes cannot be resolved without
experimental evidence.
To date, no speciﬁc inhibitors of AS3MT have been
identiﬁed. Our approach was to identify small molecules that
bind to hAS3MT and either inhibit or activate. The objective of
this study was to identify small molecules that bind to hAS3MT
and aﬀect enzymatic activity. These small molecules would be
the starting point for future development of drugs to prevent
arsenic-related disease. The small molecules should be selective
for As(III) methyltransferases, and preferably, binding should
not be competitive with As(III) or SAM. This required
development of a high-throughput assay that could be used to
screen small molecule libraries.20 This TR-FRET assay was
adapted to screen for inhibitors, and modiﬁcations might allow
it to screen for activators in future experiments.
We used this assay to screen synthetic mixture based libraries
that have been used successfully in the identiﬁcation of small
molecule inhibitors over the last two decades.21,22 From a
mixture based scaﬀold ranking library of over 30 million small
Figure 2. Dose−response relationship of TPIMS inhibitors and hAS3MT activity. The activity of hAS3MT was assayed as described in the legend to
Figure 1 in the presence of the indicated concentrations of (A) TPI-2; (B) TPI-4; (C) TPI-5; or (D) TPI-6. The inhibitor concentrations of half-
maximal inhibition (IC50) were calculated as 38 μM for TPI-2, 51 μM for TPI-5, 31 μM for TPI-5, and 38 μM for TPI-6. The data were ﬁtted using
SigmaPlot. The data are the mean ± SE (n = 3).
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molecule compounds, we identiﬁed 10 compounds that inhibit
hAS3MT. The TPIMS inhibitors did not prevent binding of
As(III), indicating noncompetitive binding at a site distinct
from the substrate binding site. All 10 inhibit As(III)
methylation, but only 5 inhibit MAs(III) methylation,
indicating diﬀerences in their mechanism of action. We
proposed that AS3MT undergoes diﬀerent conformational
changes during the two methylation steps that may account for
the diﬀerential action of the inhibitors.9,45 Importantly, the
latter observation means that at least those ﬁve do not inhibit
SAM binding, or they would have inhibited all methyltransfer-
ase activity. TPI-4 also does not inhibit COMT activity,
demonstrating selectivity for AS3MT. COMT is one of the few
SAM MTs that is commercially available and has a convenient
assay. In future experiments, the eﬀect of the inhibitors on
other members of the superfamily should be examined.
Crystallography has been instrumental in rational structure-
based drug design.46 In silico docking of the TPIMS
compounds was conducted using the crystal structure of an
hAS3MT orthologue.25 There were no constraints imposed on
the docking, just that the ﬁnal solution should have the lowest
free energy. It is signiﬁcant that the lowest free energy site for
all 10 inhibitors were at approximately the same location on the
surface of the enzyme. While the diﬀerences in the binding
aﬃnity and inhibitory properties among the 10 cannot be
deduced from the docking analysis, the fact that they are all
predicted to bind at a similar region of the enzyme suggests that
this is a site worthy of further analysis. Although AS3MT is a
member of the large superfamily of SAM methyltransferases,
the structure of the enzyme at the inhibitor binding site is
unique in AS3MT and not found in other members of the
superfamily.25 As noncompetitive inhibitors, their binding to a
site distant from the substrate binding site implies a
conformational change that may be regulatory and not linear
with substrate binding. Noncompetitive inhibitors often bind to
allosteric sites in enzymes. For example, a similar docking
analysis of binding of 6-hydroxyﬂavon, a noncompetitive
inhibitor of cytochrome P-450 2C9, indicates that it binds to
Figure 3. Eﬀect of TPIMS inhibitors on individual methylation steps.
The activity of hAS3MT was assayed by HPLC-ICP-MS, as described
under Materials and Methods. The assay contained TPIMS
compounds at 50 μM each and 2 μM hAS3MT, ﬁnal concentrations.
The reactions were terminated by the addition of 6% (v/v) H2O2 after
4 h at 37 °C to oxidize all arsenic species, which were speciated by
HPLC-ICP-MS. (A) Both methylation steps contribute to the
methylation of 10 μM As(III) methylation. (B and C) Only the
second methylation step is required for methylation of 10 μM
MAs(III). (B) TPIMS compounds that inhibit MAs(III) methylation.
(C) TPIMS compounds that do not inhibit MAs(III) methylation.
Figure 4. Eﬀect of TPIMS compound binding of As(III) or MAs(III)
to AS3MT. Substrate binding was estimated from the quenching of the
ﬂuorescence of the single-tryptophan CrArsM Y72W enzyme, as
described under Materials and Methods. The 5 μM enzyme was
preincubated with individual TPIMS compounds at 50 μM ﬁnal
concentration for 5 min on ice prior to the initiation of the assay with
either (A) As(III) or (B) MAs(III) at the indicated concentrations.
Black circle, no addition; open circle, TPI-2; inverted black triangle,
TPI-4; open triangle, TPI-5; black square, TPI-6. The data are the
mean ± SE (n = 3).
Table 1. Comparison of Binding Properties of TPI
Compounds Calculated Using Autodock Vina33
compound
AS3MT binding
aﬃnity (kcal/mol)
AS3MT
Kd (μM)
COMT binding
aﬃnity (kcal/mol)
COMT
Kd (μM)
TPI-1 −7.3 4.5 −4.3 704
TPI-2 −8.4 0.7 −5.6 79
TPI-3 −9.3 0.2 −4.6 424
TPI-4 −8.0 1.3 −3.6 229
TPI-5 −9.4 0.1 −1.4 9410
TPI-6 −7.2 5.3 −4.7 358
TPI-7 −8.5 0.6 −5.0 216
TPI-8 −9.2 0.2 −2.2 2440
TPI-9 −8.8 0.5 −0.7 306800
TPI-10 −9.0 0.3 −5.5 93
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the same allosteric regulatory site as warfarin,47 an important
drug for treatment of blood clotting.48 An allosteric site on
AS3MT implies that cells regulate its activity. A search for
physiological regulators may be productive. In addition, a
regulatory site could be a target for future development of
modulators of hAS3MT activity. Future studies will be directed
at cocrystallization of hAS3MT and orthologues with inhibitors
and design of new inhibitors with high aﬃnity as candidates of
drug development, as well as understanding of the arsenic
methylation mechanism. Meanwhile, these inhibitors will serve
as useful reagents for research on the molecular mechanism of
AS3MT.
■ CONCLUSIONS
New high-throughput assays and crystal structures have allowed
the identiﬁcation of synthetic small molecule inhibitors of
AS3MT, the enzyme that activates arsenic into more highly
toxic and potentially carcinogen species. The inhibitors bind to
a potential allosteric site on the surface of AS3MT, suggesting
physiological regulation of arsenic methylation. These small
molecule inhibitors are the starting point for the development
of drugs to prevent arsenic-related diseases.
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